Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalNot applicablepeer-review

View graph of relations

Author(s)

  • Christopher Alvarez-Breckenridge
  • Julie J. Miller
  • Naema Nayyar
  • Corey M. Gill
  • Andrew Kaneb
  • Megan D’Andrea
  • Long P. Le
  • Jesse Lee
  • Ju Cheng
  • William E. Butler
  • Pratik Multani
  • Edna Chow Maneval
  • Sun Ha Paek
  • Brian D. Toyota
  • Dora Dias-Santagata
  • Sandro Santagata
  • Javier Romero
  • Alice T. Shaw
  • Anna F. Farago
  • Stephen Yip
  • Daniel P. Cahill
  • Tracy T. Batchelor
  • A. John Iafrate
  • Priscilla K. Brastianos

Detail(s)

Original languageEnglish
Article number5
Journal / Publicationnpj Precision Oncology
Volume1
Publication statusPublished - 20 Mar 2017
Externally publishedYes

Abstract

Glioneuronal tumors constitute a histologically diverse group of primary central nervous system neoplasms that are typically slow-growing and managed conservatively. Genetic alterations associated with glioneuronal tumors include BRAF mutations and oncogenic fusions. To further characterize this group of tumors, we collected a cohort of 26 glioneuronal tumors and performed indepth genomic analysis. We identified mutations in BRAF (34%) and oncogenic fusions (30%), consistent with previously published reports. In addition, we discovered novel oncogenic fusions involving members of the NTRK gene family in a subset of our cohort. One-patient with BCAN exon 13 fused to NTRK1 exon 11 initially underwent a subtotal resection for a 4th ventricular glioneuronal tumor but ultimately required additional therapy due to progressive, symptomatic disease. Given the patient’s targetable fusion, the patient was enrolled on a clinical trial with entrectinib, a pan-Trk, ROS1, and ALK (anaplastic lymphoma kinase) inhibitor. The patient was treated for 11 months and during this time volumetric analysis of the lesion demonstrated a maximum reduction of 60% in the contrast-enhancing tumor compared to his pre-treatment magnetic resonance imaging study. The radiologic response was associated with resolution of his clinical symptoms and was maintained for 11 months on treatment. This report of a BCAN-NTRK1 fusion in glioneuronal tumors highlights its clinical importance as a novel, targetable alteration.

Citation Format(s)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. / Alvarez-Breckenridge, Christopher; Miller, Julie J.; Nayyar, Naema; Gill, Corey M.; Kaneb, Andrew; D’Andrea, Megan; Le, Long P.; Lee, Jesse; Cheng, Ju; Zheng, Zongli; Butler, William E.; Multani, Pratik; Chow Maneval, Edna; Ha Paek, Sun; Toyota, Brian D.; Dias-Santagata, Dora; Santagata, Sandro; Romero, Javier; Shaw, Alice T.; Farago, Anna F.; Yip, Stephen; Cahill, Daniel P.; Batchelor, Tracy T.; Iafrate, A. John; Brastianos, Priscilla K.

In: npj Precision Oncology, Vol. 1, 5, 20.03.2017.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalNot applicablepeer-review